Piyasa kapalı· · EUR · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
Why GVS stock is in focus after fresh half year earnings GVS (BIT:GVS) is back on investors’ radar after reporting half year 2026 results on 6 August, with broadly steady sales and revenue but a sharp move in net income. See our latest analysis for GVS. The half year results appear to have reset expectations around GVS, with the stock posting a 1 day share price return of 9.52% and a 90 day share price return of 17.27%. However, the 5 year total shareholder return is down 66.14%, which shows...
GVS SpA (LTS:0GV5) delivers solid H1 2026 with margin expansion and strong pricing power, while management maintains prudent guidance amid geopolitical complexity.
MILAN, June 17, 2026--WISE S.p.A., a pioneering medical device company specializing in advanced implantable electrodes for neuromonitoring, neuromodulation, and brain-computer interface (BCI), today announced the successful closing of an oversubscribed Series D financing round totaling €30 million. The round was joined by ENEA Tech and Biomedical, an Italian foundation dedicated to innovation and technology transfer in the biomedical sector, which enters WISE's investor base as a strategic partn
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.